These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1450043)

  • 41. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of severe hypercalcaemia with mithramycin and aminohydroxypropylidene bisphosphonate.
    Ralston SH; Gallacher SJ; Dryburgh FJ; Cowan RA; Boyle IT
    Lancet; 1988 Jul; 2(8605):277. PubMed ID: 2899259
    [No Abstract]   [Full Text] [Related]  

  • 43. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
    Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
    Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
    Atula ST; Tähtelä RK; Nevalainen JI; Pylkkänen LH
    Acta Oncol; 2003; 42(7):735-40. PubMed ID: 14690159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
    Wimalawansa SJ
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
    Cantwell BM; Harris AL
    Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
    Sims EC; Rogers PB; Besser GM; Plowman PN
    Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
    Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
    Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
    Gallacher SJ; Ralston SH; Fraser WD; Dryburgh FJ; Cowan RA; Logue FC; Boyle IT
    Bone Miner; 1991 Dec; 15(3):249-56. PubMed ID: 1773137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
    Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
    Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction.
    Palmer S; Tillman F; Sharma P; Auten J; Owen K; Clark SM; Morgan KP
    Ann Pharmacother; 2021 Mar; 55(3):303-310. PubMed ID: 32847379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
    Gurney H; Kefford R; Stuart-Harris R
    Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A; Graves L
    South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.